The role of DAB2IP in androgen receptor activation during prostate cancer progression

Oncogene

Volumn 33, Issue 15, 2014, Pages 1954-1963

  Wu, K ^a,b   Liu, J ^a   Tseng, S F ^c   Gore, C ^a   Ning, Z ^b   Sharifi, N ^a   Fazli, L ^d   Gleave, M ^d   Kapur, P ^a   Xiao, G ^e   Sun, X ^a   Oz, O K ^a   Min, W ^f   Alexandrakis, G ^c   Yang, C R ^g   Hsieh, C L ^g,h   Wu, H C ^g,i   He, D ^b   Xie, D ^j   Hsieh, J T ^a,g  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^c The University of Texas at Arlington   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h ASIA UNIVERSITY   (Taiwan)

ⁱ CHINA MEDICAL UNIVERSITY   (Taiwan)

^j HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

more..

Author keywords

androgen receptor; DAB2IP; genomic pathway; prostate cancer; Src

Indexed keywords

ANIMALS; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MICE; MICE, KNOCKOUT; PROSTATIC NEOPLASMS; RAS GTPASE-ACTIVATING PROTEINS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84899446436     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.143     Document Type: Article

References (49)

1. Huggins C, Hodges CV. Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate (Reprinted from Cancer Res, vol 1, pg 293-297, 1941). J Urol 2002; 167: 948-951
2. Heinlein CA, Chang CS. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308
3. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45
4. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401-406
5. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: Cellular and molecular biology. Endocr Rev 1999; 20: 321-344
6. Brooke GN, Bevan CL. The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 2009; 10: 18-25
7. Watson PA, Chen YNF, Balbas MD, Wongvipat J, Socci ND, Viale A, et al. Constitutively active androgen receptor splice variants expressed in castrationresistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010; 107: 16759-16765
8. Guo ZY, Yang X, Sun F, Jiang RC, Linn DE, Chen HG, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69: 2305-2313
9. Sun SH, Sprenger CCT, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120: 2715-2730
10. Shang YF, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002; 9: 601-610
11. Wang QB, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007; 27: 380-392
12. Wang QB, Carroll JS, Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 2005; 19: 631-642
13. Wen Y, Hu MCT, Makino K, Spohn B, Bartholomeusz G, Yan DH, et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000; 60: 6841-6845
14. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999; 5: 280-285
15. Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, et al. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer-characterization of a novel GTPase-Activating protein associated with N-Terminal domain of DOC-2/DAB2. J Biol Chem 2002; 277: 12622-12631
16. Xie DX, Gore C, Zhou J, Pong RC, Zhang HF, Yu LY, et al. DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc Natl Acad Sci USA 2009; 106: 19878-19883
17. Chen H, Toyooka S, Gazdar AF, Hsieh JT. Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem 2003; 278: 3121-3130
18. Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005; 280: 22437-22444
19. Yano M, Toyooka S, Tsukuda K, Dote H, Ouchida M, Hanabata T, et al. Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer 2005; 113: 59-66
20. Dote H, Toyooka S, Tsukuda K, Yano M, Ota T, Murakami M, et al. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. Br J Cancer 2005; 92: 1117-1125
21. Dote H, Toyooka S, Tsukuda K, Yano M, Ouchida M, Doihara H, et al. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res 2004; 10: 2082-2089
22. Qiu GH, Xie HM, Wheelhouse N, Harrison D, Chen GG, Salto-Tellez M, et al. Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma. J Hepatol 2007; 46: 655-663
23. Xie DX, Gore C, Liu J, Pong RC, Mason R, Hao GY, et al. Role of DAB2IP in modulating epithelial-To-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci USA 2010; 107: 2485-2490
24. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, et al. An oncogene-Tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappa B. Nat Med 2010; 16: 286-U282
25. Gioeli D, Black BE, Gordon V, Spencer A, Kesler CT, Eblen ST, et al. Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol 2006; 20: 503-515
26. Kesler CT, Gioeli D, Conaway MR, Weber MJ, Paschal BM. Subcellular localization modulates activation function 1 domain phosphorylation in the androgen receptor. Mol Endocrinol 2007; 21: 2071-2084
27. Chen S, Gulla S, Cai C, Balk SP. Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem 2012; 287: 8571-8583
28. Gordon V, Bhadel S, Wunderlich W, Zhang J, Ficarro SB, Mollah SA, et al. CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol 2010; 24: 2267-2280
29. Min W, Lin Y, Tang SB, Yu LY, Zhang HF, Wan T, et al. AIP1 recruits phosphatase PP2A to ASK1 in tumor necrosis factor-induced ASK1-JNK activation. Circ Res 2008; 102: 840-848
30. Yang CS, Vitto MJ, Busby SA, Garcia BA, Kesler CT, Gioeli D, et al. Simian virus 40 small t antigen mediates conformation-dependent transfer of protein phosphatase 2A onto the androgen receptor. Mol Cell Biol 2005; 25: 1298-1308
31. Verras M, Brown J, Li XM, Nusse R, Sun ZJ. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res 2004; 64: 8860-8866
32. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69: 16-22
33. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69: 2305-2313
34. Cao WH, Luttrell LM, Medvedev AV, Pierce KL, Daniel KW, Dixon TM, et al. Direct binding of activated c-Src to the beta(3)-Adrenergic receptor is required for MAP kinase activation. J Biol Chem 2000; 275: 38131-38134
35. Wright CD, Chen QH, Baye NL, Huang Y, Healy CL, Kasinathan S, et al. Nuclear alpha 1-Adrenergic receptors signal activated Erk localization to caveolae in adult cardiac myocytes. Circ Res 2008; 103: 992-1000
36. Zhou XE, Suino-Powell KM, Li J, He YZ, MacKeigan JP, Melcher K, et al. Identification of SRC3/AIB1 as a preferred coactivator for hormone-Activated androgen receptor. J Biol Chem 2010; 285: 9161-9171
37. Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB21P. J Natl Cancer Inst 2007; 99: 1836-1844
38. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351: 1488-1490
39. Chen H, Toyooka S, Gazdar AF, Hsieh JT. Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem 2003; 278: 3121-3130
40. Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005; 280: 22437-22444
41. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, et al. An oncogene-Tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010; 16: 286-294
42. Vidal M, Gigoux V, Garbay C. SH2 and SH3 domains as targets for anti-proliferative agents. Crit Rev Oncol Hematol 2001; 40: 175-186
43. Mayer BJ. SH3 domains: Complexity in moderation. J Cell Sci 2001; 114: 1253-1263
44. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15: 7421-7428
45. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study. Cancer 2012; 118: 63-71
46. Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. Src family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009; 15: 3540-3549
47. Cai HJ, Babic I, Wei X, Huang JT, Witte ON. Invasive prostate carcinoma driven by c-Src and androgen receptor synergy. Cancer Res 2011; 71: 862-872
48. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120: 2715-2730
49. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481